MTAP Deletion as a Therapeutic Vulnerability in Cancer: From Molecular Mechanism to Clinical Targeting
International Journal of Molecular Sciences · 11.12.2025 · 26 (24) · 11956
DOI: 10.3390/ijms262411956 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.12.2025. Verfasst von Paweł Krawczyk und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunology and Genetics, Chair of Internal Diseases, Medical University of Lublin, 20-059 Lublin, Poland. Hauptthemen laut MEDLINE: Purine-Nucleoside Phosphorylase, Neoplasms, Gene Deletion. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The MTAP (methylthioadenosine phosphorylase) gene, located on chromosome 9p21, plays a crucial role in the methionine salvage pathway and is frequently co-deleted with CDKN2A in various malignancies. Loss of MTAP expression leads to the accumulation of methylthioadenosine (MTA), which selectively inhibits protein arginine methyltransferase 5 (PRMT5) and creates a unique metabolic vulnerability in MTAP-deficient tumors. These alterations have emerged as promising therapeutic targets in precision oncology. Recent advances highlight the potential of exploiting MTAP loss through synthetic lethality approaches using PRMT5 and methionine adenosyltransferase 2A (MAT2A) inhibitors. Preclinical and early clinical data indicate that targeting these pathways can selectively impair tumor growth while sparing MTAP-proficient cells. Moreover, MTAP deletion has been associated with specific molecular and immunologic profiles that may influence treatment response and tumor microenvironment characteristics. This review summarizes current knowledge on the biological functions of MTAP, the mechanisms linking its loss to oncogenesis, and the evolving landscape of therapeutic strategies targeting MTAP-deficient cancers. Understanding these molecular dependencies offers novel opportunities for the development of precision-based therapies across diverse tumor types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Immunology and Genetics, Chair of Internal Diseases, Medical University of Lublin, 20-059 Lublin, Poland.
- Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-059 Lublin, Poland.
ORCID-Profile: Kamila Wojas-Krawczyk
Zitieren
APA
Krawczyk, P., & Wojas-Krawczyk, K. (2025). MTAP Deletion as a Therapeutic Vulnerability in Cancer: From Molecular Mechanism to Clinical Targeting. International Journal of Molecular Sciences, 26(24), 11956. https://doi.org/10.3390/ijms262411956
Vancouver
Krawczyk P, Wojas-Krawczyk K. MTAP Deletion as a Therapeutic Vulnerability in Cancer: From Molecular Mechanism to Clinical Targeting. International Journal of Molecular Sciences. 2025;26(24):11956. doi:10.3390/ijms262411956
BibTeX
@article{Krawczyk2025,
author = {Krawczyk, Paweł and Wojas-Krawczyk, Kamila},
title = {MTAP Deletion as a Therapeutic Vulnerability in Cancer: From Molecular Mechanism to Clinical Targeting},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {24},
pages = {11956},
doi = {10.3390/ijms262411956}
}
EUVIMED